A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone

Trial Profile

A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Apr 2018 Results of analysis assessing predictive biomarkers for Abiraterone Acetate treatment response and understand the mechanisms related to treatment resistance by analysing patient samples from this and one more trial (protocol number:- H12-02547, University of British Columbia - British Columbia Cancer Agency Research Ethics Board) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top